The GalNAc–asiRNA therapeutics that OliX is currently developing target an array of liver diseases, including non-alcoholic steatohepatitis (NASH) with fibrosis, hepatitis B virus, and ...

OliX Pharmaceuticals, the first Asian company to advance its own proprietary RNA interference (RNAi) technology platform into the clinic, is using RNAi technology to treat skin, eye and lung ...